Division of Neonatology
The Division of Neonatology has a robust research program that focuses on several key areas: understanding the fundamental biology of preterm birth and its complications, rigorously testing new therapeutics in newborns through expertly designed clinical trials, developing new knowledge about risk factors for poor outcomes in sick neonates through rigorous observational studies, and developing new understanding of the social and medical impact of the organization and economy of healthcare delivery structures on maternal and child health.
The research strengths in the Division of Neonatology include a health services and maternal-child health epidemiology research core focusing on health care systems, social determinants of health, quality care assessment, and environmental-genetic drivers of adverse perinatal outcomes. The Division has recognized strength in neonatal follow-up and outcomes research; laboratory research into the fetal origins of adult disease, the causes of preterm birth and fetal growth restriction, inflammatory lung diseases, and drug discovery for rare genetic diseases; and research in neonatal infectious disease, antibiotic stewardship and the microbiome and its impact of long term health.
In addition, the Division also serves as a national leader in the development and conduct of multicenter and single-center clinical trials. As a member of the National Institute of Child Health and Human Development Neonatal Research Network, the Division is at the forefront of academic centers in clinical and epidemiological research in the U.S.
Through Children's Hospital of Philadelphia Frontier Program, the Division of Neonatology is the only center in the country investigating the novel therapeutic intervention of liquid ventilation, which holds a potential for commercialization of a radical new therapy for neonatal lung disease and injury.